↓ Skip to main content

Adipose Stromal Vascular Fraction‐Mediated Improvements at Late‐Stage Disease in a Murine Model of Multiple Sclerosis

Overview of attention for article published in Stem Cells, November 2016
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Good Attention Score compared to outputs of the same age (79th percentile)
  • Good Attention Score compared to outputs of the same age and source (65th percentile)

Mentioned by

twitter
15 X users
facebook
1 Facebook page

Citations

dimensions_citation
41 Dimensions

Readers on

mendeley
61 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Adipose Stromal Vascular Fraction‐Mediated Improvements at Late‐Stage Disease in a Murine Model of Multiple Sclerosis
Published in
Stem Cells, November 2016
DOI 10.1002/stem.2516
Pubmed ID
Authors

Annie C. Bowles, Amy L. Strong, Rachel M. Wise, Robert C. Thomas, Brittany Y. Gerstein, Maria F. Dutreil, Ryan S. Hunter, Jeffrey M. Gimble, Bruce A. Bunnell

Abstract

Multiple sclerosis (MS) is a common neurodegenerative disease and remains an unmet clinical challenge. In MS, an autoimmune response leads to immune cell infiltration, inflammation, demyelination, and lesions in central nervous system (CNS) tissues resulting in tremors, fatigue, and progressive loss of motor function. These pathologic hallmarks are effectively reproduced in the murine experimental autoimmune encephalomyelitis (EAE) model. The stromal vascular fraction (SVF) of adipose tissue is composed of adipose-derived stromal/stem cells (ASC), adipocytes, and various leukocytes. The SVF can be culture expanded to generate ASC lines. Clinical trials continue to demonstrate the safety and efficacy of ASC therapies for treating several diseases. However, little is known about the effectiveness of the SVF for neurodegenerative diseases, such as MS. At late-stage disease, EAE mice show severe motor impairment. The goal for these studies was to test the effectiveness of SVF cells and ASC in EAE mice after the onset of neuropathology. The clinical scoring, behavior, motor function, and histopathologic analyses revealed significant improvements in EAE mice treated with the SVF or ASC. Moreover, SVF treatment mediated more robust improvements to CNS pathology than ASC treatment based on significant modulations of inflammatory factors. The most pronounced changes following SVF treatment were the high levels of interleukin-10 in the peripheral blood, lymphoid and CNS tissues along with the induction of regulatory T cells in the lymph nodes which indicate potent immunomodulatory effects. The data indicate SVF cells effectively ameliorated the EAE immunopathogenesis and supports the potential use of SVF for treating MS. This article is protected by copyright. All rights reserved.

X Demographics

X Demographics

The data shown below were collected from the profiles of 15 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 61 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 61 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 10 16%
Researcher 8 13%
Student > Bachelor 7 11%
Professor > Associate Professor 3 5%
Student > Master 3 5%
Other 9 15%
Unknown 21 34%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 10 16%
Medicine and Dentistry 9 15%
Neuroscience 4 7%
Agricultural and Biological Sciences 3 5%
Engineering 3 5%
Other 8 13%
Unknown 24 39%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 9. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 02 March 2017.
All research outputs
#3,721,056
of 22,893,031 outputs
Outputs from Stem Cells
#995
of 3,904 outputs
Outputs of similar age
#62,883
of 312,991 outputs
Outputs of similar age from Stem Cells
#18
of 52 outputs
Altmetric has tracked 22,893,031 research outputs across all sources so far. Compared to these this one has done well and is in the 83rd percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,904 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.6. This one has gotten more attention than average, scoring higher than 74% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 312,991 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 79% of its contemporaries.
We're also able to compare this research output to 52 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 65% of its contemporaries.